澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

CLARITY PHARMACEUTICALS LTD

3.510

+0.0401.15%

成交量：141.02万

成交额：496.69万

市值：13.06亿

市盈率：-17.43

高：3.620

开：3.450

低：3.370

收：3.470

52周最高：5.870

52周最低：1.430

股本：3.72亿

流通股本：2.74亿

量比：0.45

换手率：0.51%

股息：- -

股息率：- -

每股收益(TTM):-0.201

每股收益(LYR):-0.201

净资产收益率：-54.37%

总资产收益率：-33.76%

市净率：14.47

市盈率(LYR):-17.43

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Clarity Pharmaceuticals表示靶向铜诊疗产品及临床开发项目不受美国100%关税影响

CLARITY PHARMACEUTICALS LTD确认美国临床试验的同位素及药品制造商均设在美国本土

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CU6.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":3.51,"timestamp":1771564320000,"preClose":3.47,"halted":0,"volume":1410248,"delay":0,"changeRate":0.011527377521613714,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.201427,"marketStatus":"休市中","change":0.04,"latestTime":"02-20 16:12:00 AEDT","open":3.45,"high":3.62,"low":3.37,"amount":4966915,"amplitude":0.072046,"askPrice":3.53,"askSize":3333,"bidPrice":3.5,"bidSize":2855,"shortable":3,"etf":0,"ttmEps":-0.201427,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1771801200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":3.47,"openAndCloseTimeList":[[1771542000000,1771563600000]],"volumeRatio":0.44569514921108694,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-33.76%","roe":"-54.37%","lyrEps":-0.201427,"volumeRatio":0.44569514921108694,"shares":372030071,"dividePrice":0,"high":3.62,"amplitude":0.072046,"preClose":3.47,"low":3.37,"week52Low":1.43,"pbRate":"14.47","psRate":"138.00","week52High":5.87,"institutionHeld":0,"latestPrice":3.51,"committee":-0.077246,"eps":-0.201427,"divideRate":0,"volume":1410248,"delay":0,"ttmEps":-0.201427,"open":3.45,"prevYearClose":3.38,"prevWeekClose":2.86,"prevMonthClose":3.07,"prevQuarterClose":3.38,"fiveDayClose":2.86,"twentyDayClose":3.29,"sixtyDayClose":3.64,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142166450","title":"Clarity Pharmaceuticals表示靶向铜诊疗产品及临床开发项目不受美国100%关税影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1142166450","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142166450?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856278,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals宣布，公司的靶向铜诊疗产品以及相关临床开发项目将不会受到美国实施的100%关税政策影响。\n该公司强调，尽管面临新的贸易政策挑战，其核心业务运营和产品开发计划仍将按既定方向推进，确保为患者提供创新的诊疗解决方案不会因外部贸易环境变化而受到干扰。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"1176194720","title":"CLARITY PHARMACEUTICALS LTD确认美国临床试验的同位素及药品制造商均设在美国本土","url":"https://stock-news.laohu8.com/highlight/detail?id=1176194720","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176194720?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856277,"startTime":"0","endTime":"0","summary":"CLARITY PHARMACEUTICALS LTD日前宣布，该公司已确认为其美国临床试验站点提供服务的所有同位素和药物产品制造商均位于美国境内。\n这一确认表明，CLARITY PHARMACEUTICALS LTD在美国开展的临床试验项目将完全依托本土制造商的产能和服务，确保供应链的稳定性和合规性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CU6.AU\",params:#limit:6,delay:true,,,undefined,":[]}}